drugset

drugset / Trial / NCT04348409

Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

NCT04348409 ↗

Completed 50 enrolled Azidus Brasil Centro de Genomas - UNIFESP · collab Emilio Ribas Institute of Infectious Diseases · collab Farmoquimica S.A. · collab Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil · collab Hospital Vera Cruz · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg BID) to treat hospitalized patients with moderate COVID-19.

Timeline

Start: 2020-05-25
Primary completion: 2020-12-31
Completion: 2020-12-31

Publications

Blum VF, Cimerman S, Hunter JR, Tierno P, Lacerda A, Soeiro A, Cardoso F, Bellei NC, Maricato J, Mantovani N, Vassao M, Dias D, Galinskas J, Janini LMR, Santos-Oliveira JR, Da-Cruz AM, Diaz RS. Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine. 2021 Jul;37:100981. doi: 10.1016/j.eclinm.2021.100981. Epub 2021 Jun 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nitazoxanide	Other / unclassified	600 mg	—

Indications